Hospital Universitario Virgen De La Victoria

At Hospital Universitario Virgen De La Victoria in Malaga, oncology research is strongly focused on neoplasms and a broad range of advanced solid tumors. The studies explore new treatment options for cancers such as breast cancer, non-small cell lung cancer, ovarian cancer, renal cell carcinoma, and pancreatic cancer, with the aim of improving disease control and treatment effectiveness.

• Testing new therapies for advanced and metastatic cancers
• Evaluating combination approaches for difficult-to-treat tumors
• Studying treatment response in tumor types with specific genetic features

The site’s large trial portfolio reflects active work in precision oncology, with research designed to refine how cancer treatments are selected and how well they perform in real-world patient groups.

A major area of research at this site is breast cancer, including HER2-positive, HER2-negative, and hormone receptor-positive disease across early, locally advanced, and metastatic settings. These trials are aimed at improving outcomes after surgery, strengthening adjuvant and neoadjuvant treatment strategies, and finding better options for patients whose disease has returned or spread.

• Studying treatment effectiveness in early and high-risk breast cancer
• Exploring new options for metastatic and treatment-resistant disease
• Assessing how tumor biology can guide personalized care

The research includes work on triple-negative breast cancer, HER2-low disease, and cancers with genetic markers such as BRCA and PIK3CA, showing a strong interest in more tailored cancer care.

Clinical trials in prostate cancer and bladder cancer are another important part of the research program, covering metastatic castration-resistant prostate cancer, high-risk localized disease, and multiple forms of non-muscle-invasive and muscle-invasive bladder cancer. The purpose of this work is to improve disease control, delay progression, and expand treatment choices for patients with limited options.

• Evaluating therapies for advanced prostate cancer
• Studying new approaches for bladder cancer subtypes
• Supporting earlier and more precise intervention in urologic cancers

This area also includes studies in renal cell carcinoma and other urinary tract malignancies, highlighting the site’s broad activity in genitourinary oncology.

The hospital conducts substantial research in hematologic malignancies and related blood disorders, including multiple myeloma, lymphomas, myelodysplastic syndromes, myelofibrosis, and acute myeloid leukemia. These studies are designed to improve response rates, reduce relapse risk, and identify better treatment strategies for both newly diagnosed and relapsed disease.

• Testing novel therapies for blood cancers
• Improving outcomes in relapsed or high-risk hematologic disease
• Exploring ways to deepen and sustain treatment response

Research in this field also includes efforts to address anemia and other complications linked to marrow disorders, reflecting a comprehensive approach to blood-related diseases.

A wide set of trials focuses on cardiovascular diseases, including atherosclerotic cardiovascular disease, heart failure, atrial fibrillation, myocardial infarction, and hypertrophic cardiomyopathy. The main goal is to prevent major events, improve long-term heart function, and assess whether new therapies can better protect patients at high risk.

• Preventing stroke, heart attack, and other major cardiovascular events
• Studying treatments for heart failure and cardiomyopathy
• Evaluating therapies for rhythm disorders and vascular risk

This research also includes prevention-focused studies in patients with elevated cardiovascular risk, showing strong activity in both treatment and risk reduction.

The site is active in metabolic disease and liver disorders, with trials in type 2 diabetes, obesity, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, and primary biliary cholangitis. These studies seek to improve metabolic control, slow liver damage, and test whether new therapies can reduce inflammation and fibrosis.

• Assessing treatments for obesity-related metabolic disease
• Studying liver fibrosis and inflammation
• Exploring options for chronic liver conditions with limited therapies

Research in this area reflects the growing link between metabolic health and long-term liver and cardiovascular outcomes.

Clinical research also covers respiratory tract diseases such as asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and progressive pulmonary fibrosis. The studies are focused on improving symptom control, reducing exacerbations, and evaluating new therapies for chronic lung disease.

• Testing therapies for severe or uncontrolled asthma
• Evaluating treatments for COPD and pulmonary fibrosis
• Improving breathing outcomes and quality of life in chronic lung disease

This area shows a strong interest in respiratory care across both inflammatory and fibrotic lung conditions.

The research portfolio includes nervous system diseases and mental disorders, with studies in migraine, multiple sclerosis, Tourette’s disorder, Alzheimer’s disease-related agitation, and depression. These trials aim to improve symptom relief, disease management, and day-to-day functioning for patients living with chronic neurologic and psychiatric conditions.

• Exploring new options for movement and behavioral disorders
• Studying treatments for chronic neurologic symptoms
• Supporting better quality of life in complex brain-related conditions

The site also participates in research on less common inherited and rare disorders, broadening its clinical trial activity beyond major disease areas.